Kevin Mcculloch Sells 90,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 90,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00. Following the sale, the insider directly owned 1,691,126 shares in the company, valued at approximately $13,579,741.78. The trade was a 5.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $8.28 on Friday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company has a 50 day moving average price of $6.61 and a 200-day moving average price of $6.63. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.62 and a 52 week high of $10.08. The firm has a market capitalization of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. As a group, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Institutional Trading of Xeris Biopharma

Several large investors have recently added to or reduced their stakes in XERS. Kestra Advisory Services LLC bought a new position in Xeris Biopharma in the fourth quarter worth approximately $25,000. KBC Group NV bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd grew its position in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on XERS shares. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.